• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

视网膜和脉络膜血管生成:新靶点综述

Retinal and choroidal angiogenesis: a review of new targets.

作者信息

Cabral Thiago, Mello Luiz Guilherme M, Lima Luiz H, Polido Júlia, Regatieri Caio V, Belfort Rubens, Mahajan Vinit B

机构信息

Edward S Harkness Eye Institute, Columbia University, New York, NY USA.

Department of Ophthalmology, Federal University of São Paulo, São Paulo, Brazil.

出版信息

Int J Retina Vitreous. 2017 Aug 21;3:31. doi: 10.1186/s40942-017-0084-9. eCollection 2017.

DOI:10.1186/s40942-017-0084-9
PMID:28835854
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5563895/
Abstract

Retinal and choroidal neovascularization are a major cause of significant visual impairment, worldwide. Understanding the various factors involved in the accompanying physiopathology is vital for development of novel treatments, and most important, for preserving patient vision. The intraocular use of anti-vascular endothelial growth factor therapeutics has improved management of the retinal and choroidal neovascularization but some patients do not respond, suggesting other vascular mediators may also contribute to ocular angiogenesis. Several recent studies examined possible new targets for future anti-angiogenic therapies. Potential targets of retinal and choroidal neovascularization therapy include members of the platelet-derived growth factor family, vascular endothelial growth factor sub-family, epidermal growth factor family, fibroblast growth factor family, transforming growth factor-β superfamily (TGF-β1, activins, follistatin and bone morphogenetic proteins), angiopoietin-like family, galectins family, integrin superfamily, as well as pigment epithelium derived factor, hepatocyte growth factor, angiopoietins, endothelins, hypoxia-inducible factors, insulin-like growth factors, cytokines, matrix metalloproteinases and their inhibitors and glycosylation proteins. This review highlights current antiangiogenic therapies under development, and discusses future retinal and choroidal pro- and anti-angiogenic targets as wells as the importance of developing of new drugs.

摘要

视网膜和脉络膜新生血管形成是全球范围内导致严重视力损害的主要原因。了解伴随的病理生理学中涉及的各种因素对于开发新的治疗方法至关重要,而最重要的是,对于保护患者视力而言。眼内使用抗血管内皮生长因子疗法改善了视网膜和脉络膜新生血管形成的治疗,但一些患者没有反应,这表明其他血管介质也可能促成眼部血管生成。最近的几项研究探讨了未来抗血管生成疗法可能的新靶点。视网膜和脉络膜新生血管形成治疗的潜在靶点包括血小板衍生生长因子家族、血管内皮生长因子亚家族、表皮生长因子家族、成纤维细胞生长因子家族、转化生长因子-β超家族(TGF-β1、激活素、卵泡抑素和骨形态发生蛋白)、血管生成素样家族、半乳糖凝集素家族、整合素超家族,以及色素上皮衍生因子、肝细胞生长因子、血管生成素、内皮素、缺氧诱导因子、胰岛素样生长因子、细胞因子、基质金属蛋白酶及其抑制剂和糖基化蛋白。本综述重点介绍了正在开发的当前抗血管生成疗法,并讨论了未来视网膜和脉络膜促血管生成和抗血管生成靶点以及开发新药的重要性。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2d21/5563895/9b987e9cda93/40942_2017_84_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2d21/5563895/9b987e9cda93/40942_2017_84_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2d21/5563895/9b987e9cda93/40942_2017_84_Fig1_HTML.jpg

相似文献

1
Retinal and choroidal angiogenesis: a review of new targets.视网膜和脉络膜血管生成:新靶点综述
Int J Retina Vitreous. 2017 Aug 21;3:31. doi: 10.1186/s40942-017-0084-9. eCollection 2017.
2
Molecular pathogenesis of retinal and choroidal vascular diseases.视网膜和脉络膜血管疾病的分子发病机制。
Prog Retin Eye Res. 2015 Nov;49:67-81. doi: 10.1016/j.preteyeres.2015.06.002. Epub 2015 Jun 23.
3
Targeting tumor micro-environment for design and development of novel anti-angiogenic agents arresting tumor growth.针对肿瘤微环境设计和开发新型抗血管生成药物以抑制肿瘤生长。
Prog Biophys Mol Biol. 2013 Nov;113(2):333-54. doi: 10.1016/j.pbiomolbio.2013.10.001. Epub 2013 Oct 15.
4
MicroRNAs in laser-induced choroidal neovascularization in mice and rats: their expression and potential therapeutic targets.小鼠和大鼠激光诱导脉络膜新生血管形成中的微小RNA:它们的表达及潜在治疗靶点
Neural Regen Res. 2021 Apr;16(4):621-627. doi: 10.4103/1673-5374.295271.
5
[Angiogenesis and retinal diseases].[血管生成与视网膜疾病]
Arq Bras Oftalmol. 2007 May-Jun;70(3):547-53. doi: 10.1590/s0004-27492007000300030.
6
Cytokines in neovascular age-related macular degeneration: fundamentals of targeted combination therapy.细胞因子在新生血管性年龄相关性黄斑变性中的作用:靶向联合治疗的基础。
Br J Ophthalmol. 2011 Dec;95(12):1631-7. doi: 10.1136/bjo.2010.186361. Epub 2011 May 5.
7
Angiogenic and antiangiogenic factors in proliferative diabetic retinopathy.增殖性糖尿病视网膜病变中的血管生成和抗血管生成因子
Curr Diabetes Rev. 2006 Feb;2(1):71-98. doi: 10.2174/157339906775473671.
8
A Proinflammatory Function of Toll-Like Receptor 2 in the Retinal Pigment Epithelium as a Novel Target for Reducing Choroidal Neovascularization in Age-Related Macular Degeneration.视网膜色素上皮细胞中Toll样受体2的促炎功能作为减少年龄相关性黄斑变性脉络膜新生血管形成的新靶点
Am J Pathol. 2017 Oct;187(10):2208-2221. doi: 10.1016/j.ajpath.2017.06.015. Epub 2017 Jul 21.
9
Intrachoroidal neovascularization in transgenic mice overexpressing vascular endothelial growth factor in the retinal pigment epithelium.视网膜色素上皮中过表达血管内皮生长因子的转基因小鼠脉络膜新生血管形成。
Am J Pathol. 2001 Mar;158(3):1161-72. doi: 10.1016/S0002-9440(10)64063-1.
10
Differential hypoxic response of human choroidal and retinal endothelial cells proposes tissue heterogeneity of ocular angiogenesis.人脉络膜和视网膜血管内皮细胞的缺氧反应差异提示眼血管生成的组织异质性。
Acta Ophthalmol. 2016 Dec;94(8):805-814. doi: 10.1111/aos.13119. Epub 2016 Jun 3.

引用本文的文献

1
Sozinibercept (Anti-VEGF-C/-D) Combined with Ranibizumab for Polypoidal Choroidal Vasculopathy: Phase IIb Predefined Subgroup Analysis.索津贝西单抗(抗VEGF-C/-D)联合雷珠单抗治疗息肉状脉络膜血管病变:IIb期预设亚组分析
Ophthalmol Sci. 2025 Mar 12;5(4):100759. doi: 10.1016/j.xops.2025.100759. eCollection 2025 Jul-Aug.
2
Evaluation of Anti-VEGFR2 Specific Photoimmunotherapy for Targeted Regression of Neovascularization in an AMD Model.在年龄相关性黄斑变性(AMD)模型中评估抗血管内皮生长因子受体2(VEGFR2)特异性光免疫疗法对新生血管靶向消退的作用。
Invest Ophthalmol Vis Sci. 2025 Jun 2;66(6):70. doi: 10.1167/iovs.66.6.70.
3
Changes in the Protein Composition of the Aqueous Humor in Patients with Glaucoma: An Update Review.

本文引用的文献

1
Bevacizumab Injection in Patients with Neovascular Age-Related Macular Degeneration Increases Angiogenic Biomarkers.贝伐单抗注射液治疗新生血管性年龄相关性黄斑变性患者可增加血管生成生物标志物。
Ophthalmol Retina. 2018 Jan;2(1):31-37. doi: 10.1016/j.oret.2017.04.004.
2
Aqueous vascular endothelial growth factor and clinical outcomes correlation after single intravitreal injection of bevacizumab in patients with neovascular age-related macular degeneration.新生血管性年龄相关性黄斑变性患者单次玻璃体内注射贝伐单抗后房水血管内皮生长因子与临床结局的相关性
Int J Retina Vitreous. 2017 May 1;3:6. doi: 10.1186/s40942-017-0066-y. eCollection 2017.
3
青光眼患者房水蛋白质组成的变化:最新综述
Int J Mol Sci. 2025 Mar 28;26(7):3129. doi: 10.3390/ijms26073129.
4
Emerging clinical evidence of a dual role for Ang-2 and VEGF-A blockade with faricimab in retinal diseases.法西单抗阻断血管生成素-2(Ang-2)和血管内皮生长因子-A(VEGF-A)在视网膜疾病中的双重作用的新临床证据。
Graefes Arch Clin Exp Ophthalmol. 2024 Dec 21. doi: 10.1007/s00417-024-06695-4.
5
The Ercc1 mouse model of XFE progeroid syndrome undergoes accelerated retinal degeneration.XFE早老症样综合征的Ercc1小鼠模型会加速视网膜退化。
Aging Cell. 2025 Mar;24(3):e14419. doi: 10.1111/acel.14419. Epub 2024 Nov 27.
6
Niosome-encapsulated auraptene reduced the mRNA expression of and genes in human retina-derived RPE cell line.脂质体包裹的金松双黄酮降低了人视网膜来源的视网膜色素上皮细胞系中[具体基因名称未给出]和[具体基因名称未给出]基因的mRNA表达。
Int J Ophthalmol. 2024 Jun 18;17(6):1028-1035. doi: 10.18240/ijo.2024.06.06. eCollection 2024.
7
Canthin-6-One Inhibits Developmental and Tumour-Associated Angiogenesis in Zebrafish.铁屎米-6-酮抑制斑马鱼的发育性血管生成和肿瘤相关血管生成。
Pharmaceuticals (Basel). 2024 Jan 12;17(1):108. doi: 10.3390/ph17010108.
8
Construction of an Exudative Age-Related Macular Degeneration Diagnostic and Therapeutic Molecular Network Using Multi-Layer Network Analysis, a Fuzzy Logic Model, and Deep Learning Techniques: Are Retinal and Brain Neurodegenerative Disorders Related?利用多层网络分析、模糊逻辑模型和深度学习技术构建渗出性年龄相关性黄斑变性诊断与治疗分子网络:视网膜与脑神经退行性疾病有关联吗?
Pharmaceuticals (Basel). 2023 Nov 2;16(11):1555. doi: 10.3390/ph16111555.
9
Correlations between subfoveal choroidal thickness, macular thickness, and visual outcome in neovascular age-related macular degeneration using swept source OCT: insights from intravitreal aflibercept treatment.使用扫频源光学相干断层扫描技术评估新生血管性年龄相关性黄斑变性患者的黄斑中心凹下脉络膜厚度、黄斑厚度与视觉预后的相关性:玻璃体内注射阿柏西普治疗的研究启示
Int J Retina Vitreous. 2023 Nov 15;9(1):70. doi: 10.1186/s40942-023-00506-4.
10
Study of aqueous humour inflammatory mediators' levels in a cohort of Egyptian patients with diabetic macular oedema.研究埃及糖尿病黄斑水肿患者房水中炎症介质水平的队列研究。
BMC Ophthalmol. 2023 Nov 14;23(1):456. doi: 10.1186/s12886-023-03192-w.
Suppression of Retinal Neovascularization by Inhibition of Galectin-1 in a Murine Model of Oxygen-Induced Retinopathy.
在氧诱导性视网膜病变小鼠模型中通过抑制半乳糖凝集素-1抑制视网膜新生血管形成
J Ophthalmol. 2017;2017:5053035. doi: 10.1155/2017/5053035. Epub 2017 Mar 24.
4
An Overview of the Fovista and Rinucumab Trials and the Fate of Anti-PDGF Medications.Fovista和利努单抗试验概述及抗血小板衍生生长因子(PDGF)药物的命运
Ophthalmic Surg Lasers Imaging Retina. 2017 Feb 1;48(2):100-104. doi: 10.3928/23258160-20170130-02.
5
Combined VEGF and PDGF inhibition for neovascular AMD: anti-angiogenic properties of axitinib on human endothelial cells and pericytes in vitro.联合抑制血管内皮生长因子(VEGF)和血小板衍生生长因子(PDGF)治疗新生血管性年龄相关性黄斑变性(neovascular AMD):阿昔替尼对人内皮细胞和周细胞的体外抗血管生成特性
Graefes Arch Clin Exp Ophthalmol. 2017 May;255(5):963-972. doi: 10.1007/s00417-017-3595-z. Epub 2017 Feb 4.
6
ANGIOPOIETIN-LIKE 4 CORRELATES WITH RESPONSE TO INTRAVITREAL RANIBIZUMAB INJECTIONS IN NEOVASCULAR AGE-RELATED MACULAR DEGENERATION.血管生成素样蛋白 4 与新生血管性年龄相关性黄斑变性对玻璃体内雷珠单抗注射的反应相关。
Retina. 2018 Mar;38(3):523-530. doi: 10.1097/IAE.0000000000001554.
7
Inhibition of Hypoxia-Induced Retinal Angiogenesis by Specnuezhenide, an Effective Constituent of Ligustrum lucidum Ait., through Suppression of the HIF-1α/VEGF Signaling Pathway.女贞子有效成分特女贞苷通过抑制HIF-1α/VEGF信号通路抑制缺氧诱导的视网膜血管生成
Molecules. 2016 Dec 21;21(12):1756. doi: 10.3390/molecules21121756.
8
Evaluating Effects of Switching Anti-Vascular Endothelial Growth Factor Drugs for Age-Related Macular Degeneration and Diabetic Macular Edema.评估抗血管内皮生长因子药物转换治疗年龄相关性黄斑变性和糖尿病性黄斑水肿的效果。
JAMA Ophthalmol. 2017 Feb 1;135(2):145-149. doi: 10.1001/jamaophthalmol.2016.4820.
9
Lebecetin, a C-type lectin, inhibits choroidal and retinal neovascularization.勒贝西汀是一种C型凝集素,可抑制脉络膜和视网膜新生血管形成。
FASEB J. 2017 Mar;31(3):1107-1119. doi: 10.1096/fj.201600351R. Epub 2016 Dec 14.
10
Fusion proteins for treatment of retinal diseases: aflibercept, ziv-aflibercept, and conbercept.用于治疗视网膜疾病的融合蛋白:阿柏西普、阿柏西普眼内注射溶液和康柏西普。
Int J Retina Vitreous. 2016 Feb 1;2:3. doi: 10.1186/s40942-016-0026-y. eCollection 2016.